Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 368 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/29/2008 First Published: 12/8/2006


1.		Phase III/IV Randomized Study of Risk-Adapted Therapy Comprising Observation Only, Combination Chemotherapy, Radiotherapy, and/or Autologous Stem Cell Transplantation in Younger Patients With Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV, Phase III				Treatment				Active				21 and under				Other				GPOH-NB2004 EU-20661, NCT00410631


2.		A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Pharmaceutical / Industry				BO21015 2008-000662-23, NCT00700180


3.		Paclitaxel Plus Carboplatin With Endostar in Patients of Advanced Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 to 75				Pharmaceutical / Industry				XYL014 NCT00708812

Last Modified: 11/24/2008 First Published: 7/1/1999


4.		Phase II/III Study of Standard and Novel Conditioning Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				4 to 70				Other				RPCI-RP-9815 NCI-V99-1527, NCT00003816, RP 98-15

Last Modified: 3/30/2007 First Published: 9/1/2002


5.		Phase II/III Randomized Study of Carboplatin and Ifosfamide With or Without Whole Body Hyperthermia in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Extraovarian Peritoneal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 65				Other				LMU-DOLPHIN-1 EU-20220, NCT00045461

Last Modified: 5/22/2007 First Published: 12/23/2003


6.		Phase II/III Randomized Pilot Study of the Timing of Surgery and Chemotherapy in Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				Adult				Other				RCOG-MRC-CHORUS EU-20350, ISRCTN74802813, NCT00075712


7.		A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 75				Other				Haema CBF SCLC UK/AS 01 NCT00168896


8.		Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 59				Other				N06IAA NCT00448266


9.		Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				OXC4T4-302 NCT00507429

Last Modified: 6/9/2008 First Published: 9/26/2007


10.		Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				4 and over				NCI				RPCI-I-72806 I 72806, NCT00536601

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute